Tonix Meds Drug Patent Portfolio
Tonix Meds owns 2 orange book drugs protected by 10 US patents Given below is the list of Tonix Meds's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10537554 | Pharmaceutical composition for treating migraine | 29 Jan, 2036 | Active |
| US11364224 | Pharmaceutical composition for treating migraine | 29 Jan, 2036 | Active |
| US9211282 | Formulations comprising triptan compounds | 19 Jul, 2031 | Active |
| US10603305 | Formulations comprising triptan compounds | 16 Jun, 2030 | Active |
| US11337962 | Formulations comprising triptan compounds | 16 Jun, 2030 | Active |
| US9610280 | Formulations comprising triptan compounds | 16 Jun, 2030 | Active |
| US9974770 | Formulations comprising triptan compounds | 16 Jun, 2030 | Active |
| US8268791 | Alkylglycoside compositions for drug administration | 09 May, 2026 | Active |
| US8440631 | Compositions for drug administration | 09 May, 2026 | Active |
| US9283280 | Compositions for drug administration | 09 May, 2026 | Active |
Latest Legal Activities on Tonix Meds's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Tonix Meds.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 14 May, 2024 | US10603305 |
|
Email Notification
Critical
| 07 May, 2024 | US9974770 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 07 May, 2024 | US9974770 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 25 Apr, 2024 | US11337962 |
|
Email Notification
Critical
| 25 Apr, 2024 | US11337962 |
|
Email Notification
Critical
| 24 Apr, 2024 | US10537554 |
|
Email Notification
Critical
| 24 Apr, 2024 | US9211282 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 24 Apr, 2024 | US11364224 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 24 Apr, 2024 | US9211282 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 24 Apr, 2024 | US10603305 |
|
Email Notification
Critical
| 24 Apr, 2024 | US10603305 |
|
Email Notification
Critical
| 24 Apr, 2024 | US9610280 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 24 Apr, 2024 | US9610280 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 24 Apr, 2024 | US10537554 |
|
Email Notification
Critical
| 24 Apr, 2024 | US11364224 |
Tonix Meds's Family Patents
Tonix Meds Drug List
Given below is the complete list of Tonix Meds's drugs and the patents protecting them.
1. Tosymra
Tosymra is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9211282 | Formulations comprising triptan compounds |
19 Jul, 2031
(6 years from now)
| Active |
| US10603305 | Formulations comprising triptan compounds |
16 Jun, 2030
(5 years from now)
| Active |
| US11337962 | Formulations comprising triptan compounds |
16 Jun, 2030
(5 years from now)
| Active |
| US9610280 | Formulations comprising triptan compounds |
16 Jun, 2030
(5 years from now)
| Active |
| US9974770 | Formulations comprising triptan compounds |
16 Jun, 2030
(5 years from now)
| Active |
| US8268791 | Alkylglycoside compositions for drug administration |
09 May, 2026
(1 year, 5 months from now)
| Active |
| US8440631 | Compositions for drug administration |
09 May, 2026
(1 year, 5 months from now)
| Active |
| US9283280 | Compositions for drug administration |
09 May, 2026
(1 year, 5 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tosymra's drug page
2. Zembrace Symtouch
Zembrace Symtouch is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10537554 | Pharmaceutical composition for treating migraine |
29 Jan, 2036
(11 years from now)
| Active |
| US11364224 | Pharmaceutical composition for treating migraine |
29 Jan, 2036
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zembrace Symtouch's drug page